ライフサイエンスコーパス: Cancer Center

1 sorectal excision (TME) at an NCI designated cancer center.

2 15, 2015, at the Dana-Farber/Brigham Women's Cancer Center.

3 terrogation data following RT at an academic cancer center.

4 and December 31, 2012, at a single tertiary cancer center.

5 ment of Breast Medical Oncology, MD Anderson Cancer Center.

6 iary medical center with a designated breast cancer center.

7 iety, National Cancer Institute, MD Anderson Cancer Center.

8 r to follow patients in collaboration with a cancer center.

9 re Tech, and University of Texas MD Anderson Cancer Center.

10 T and the hepatobilary cancer clinics at the cancer center.

11 chemotherapy varied significantly by type of cancer center.

12 est Oncology Group [SWOG]) or at MD Anderson Cancer Center.

13 s, healthcare personnel, and visitors in the cancer center.

14 rtment of Oncogenetics from the A.C. Camargo Cancer Center.

15 leforSurvival Fund, Memorial Sloan-Kettering Cancer Center.

16 diatric patients at Memorial Sloan-Kettering Cancer Center.

17 dy was conducted at Memorial Sloan-Kettering Cancer Center.

18 , open-label, phase 1/2 trial at MD Anderson Cancer Center.

19 rwent mastectomy at Memorial Sloan-Kettering Cancer Center.

20 cancer and in patients treated at a tertiary cancer center.

21 clinical cohort at Memorial Sloan-Kettering Cancer Center.

22 ated with RP or EBRT at a single specialized cancer center.

23 cutive protocols at Memorial Sloan-Kettering Cancer Center.

24 database at University of Texas MD Anderson Cancer Center.

25 eated at The University of Texas MD Anderson Cancer Center.

26 al Cancer Institute-designated comprehensive cancer center.

27 an academic dermatologic surgery section and cancer center.

28 logy Service of the Memorial Sloan Kettering Cancer Center.

29 al Cancer Institute-designated comprehensive cancer center.

30 NGS (236-404 genes) in an academic tertiary cancer center.

31 2014 at the University of Texas MD Anderson Cancer Center.

32 titutes of Health and the Mayo Comprehensive Cancer Center.

33 ith untreated brain metastases from the Yale Cancer Center.

34 cember 31, 2013, in a tertiary comprehensive cancer center.

35 erapy at The University of Texas MD Anderson Cancer Center.

36 al Cancer Institute-designated comprehensive cancer center.

37 who received PST at a large US comprehensive cancer center.

38 al Cancer Institute-designated comprehensive cancer center.

39 rch 2, 2011, and May 21, 2013, at 8 academic cancer centers.

40 ternational cooperative study involved 6 eye cancer centers.

41 y/American College of Surgeons Commission on Cancer centers.

42 results may not generalize outside of major cancer centers.

43 national lymphoma clinical trials groups and cancer centers.

44 c medical center with gynecologic and breast cancer centers.

45 (NCI) as supplemental grants to existing NCI Cancer Centers.

46 when considering only affiliation with NCCN Cancer Centers.

47 mber 2007 and May 2009 from 10 United States cancer centers.

48 at non-National Cancer Institute-designated cancer centers.

49 National Comprehensive Cancer Network (NCCN) Cancer Centers.

50 Mate 067) conducted at academic and clinical cancer centers.

51 and implications for critical care units in cancer centers.

52 ical guidelines, and best practices in major cancer centers.

53 tals, but most do not contain NCI-designated cancer centers.

54 9 National Cancer Institute (NCI)-Designated Cancer Centers.

55 gists affiliated with NCI-Designated or NCCN Cancer Centers.

56 at six National Cancer Institute-designated cancer centers.

57 4 until May 2016 at Memorial Sloan Kettering Cancer Center, 10336 patients consented to tumor DNA seq

58 titutions (University of Texas M.D. Anderson Cancer Center = 164, training set; University of Rochest

59 nal cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing

60 al conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advan

61 a National Cancer Institute (NCI)-designated cancer center (8.6% [95% CI, 8.1%-9.2%] among NCI cancer

62 spital and its affiliated sites, including a cancer center, a community hospital, and outpatient imag

63 ecember 2011 at the Mass General/North Shore Cancer Center, a community-based cancer center in northe

64 at the University of Michigan Comprehensive Cancer Center, a large, hospital-based academic cancer c

65 3, was conducted at Memorial Sloan-Kettering Cancer Center, a tertiary referral center.

66 e recruited from a National Cancer Institute cancer center, a Veterans Administration Medical Center,

67 vanced cancer at a National Cancer Institute cancer center, a Veterans Affairs Medical Center, and co

68 Even at specialty cancer centers, a sizeable minority of patients with rec

69 In a comprehensive cancer center, about one fourth of the patients required

70 Cancer center accreditation and public reporting are 2 a

71 ss screening and referral as a condition for cancer center accreditation beginning in 2015.

72 , which includes 2 academic and 10 community cancer centers across Alabama, Georgia, Florida, Mississ

73 care for patients treated at eight specialty cancer centers across the United States and was used to

74 though critics have expressed concerns about cancer center advertising, analyses of the content of th

75 6.1 years and 9.0 years for the MD Anderson Cancer Center and ACOSOG cohorts, respectively.

76 a strategic alliance between M. D. Anderson Cancer Center and AstraZeneca Pharmaceuticals LP, a conc

77 After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable

78 al Cancer Institute-designated comprehensive cancer center and consented to have information stored i

79 harts of 40 such patients at a tertiary care cancer center and found that amphotericin B lipid comple

80 ic surgery units at Memorial Sloan Kettering Cancer Center and Oregon Health & Science University wer

81 spective database at the Dana-Farber/Harvard Cancer Center and selected a validation cohort from depa

82 the UCSF Helen Friller Family Comprehensive Cancer Center and the Mt Zion Health Fund of the Univers

83 12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphom

84 A survey of 71 NCI-designated cancer centers and a random sample of 71 non-NCI cancer

85 et computers in clinic waiting rooms at 9 US cancer centers and community oncology practices at 2 vis

86 s from ICC patients were obtained from three cancer centers and subjected to integrated genetic and g

87 r at National Cancer Institute Comprehensive Cancer Centers and Veterans' Administration institutions

88 Tumor samples were collected from numerous cancer centers and were examined for racial differences

89 ttee of all randomised trials at MD Anderson Cancer Center, and before a planned interim analysis of

90 ive Oncology Group, Memorial Sloan-Kettering Cancer Center, and Heng criteria).

91 r Cancer Institute, Indiana University Simon Cancer Center, and Indiana Clinical and Translational Sc

92 cer Center, a large, hospital-based academic cancer center, and report our experience with five round

93 Program, The University of Texas MD Anderson Cancer Center, and the State of Texas Rare and Aggressiv

94 targeted agents at Memorial Sloan Kettering Cancer Center are offered tumor-normal sequencing with M

95 r 1, 2013, through December 31, 2015, at the cancer center at All India Institute of Medical Sciences

96 lysis at The University of Texas MD Anderson Cancer Center based on prospectively collected data.

97 ted to the acute palliative care unit of our cancer center because of debilitating fatigue.

98 he patients were treated at The New York Eye Cancer Center, Beth Israel Comprehensive Cancer Center,

99 isolated from a patient in our comprehensive cancer center between 1 January 2006 and 15 October 2013

100 Committee on Cancer stage IV melanoma at our cancer center between 1971 and 2005.

101 s were performed at Memorial Sloan Kettering Cancer Center between 1992 and 2012, from which 2368 pat

102 This trial was done at MD Anderson Cancer Center between 1999 and 2001 (protocol number 98-

103 ancreatic NETs treated at the H. Lee Moffitt Cancer Center between 1999 and 2010 were assigned a stag

104 Lee Moffitt Cancer Center between 1999 and 2010 were assigned a stag

105 ort) and 904 patients at the Korean National Cancer Center between 2000 and 2003 (validation cohort).

106 eocecal NETs who were treated at the Moffitt Cancer Center between 2000 and 2010 were assigned stages

107 nd industry trials activated in the CTD of a cancer center between 2007 and 2011.

108 III breast cancer who were seen at a single cancer center between 2010 and 2012, and who agreed to p

109 matology Service at Memorial Sloan Kettering Cancer Center between January 1, 2014, and December 31,

110 PDAC and hospitalized at the China National Cancer Center between January 1999 and January 2016 were

111 ion for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2005 and December 2009 and

112 with MDS who were referred to M. D. Anderson Cancer Center between September 2005 and December 2009.

113 py at 6 National Cancer Institute-designated cancer centers between January 1, 2004, and December 31,

114 carcinoma treated at the Dana-Farber/Harvard Cancer Center (Boston, MA, USA).

115 undergone (18)F-FDG PET at the M.D. Anderson Cancer Center both before and up to 3.5 mo after undergo

116 dian Institutes of Health Research, Abramson Cancer Center, Centre for Addiction and Mental Health Fo

117 ent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] cohort) and 117 (Cambridge

118 with the effect of CRp in the M.D. Anderson Cancer Center cohort.

119 Neither admission to ICUs in cancer centers compared with general hospitals nor annua

120 The number of patients managed in major cancer centers creates a challenge to the implementation

121 By Memorial Sloan-Kettering Cancer Center criteria, 82% of patients had intermediate

122 Examples from the Memorial Sloan-Kettering Cancer Center CST program are incorporated.

123 ilability of palliative care services in the cancer center, defined as the presence of at least 1 pal

124 oscopy course (2014 Memorial Sloan Kettering Cancer Center dermoscopy course).

125 y of hematology-oncology fellows training at cancer centers designated by the National Cancer Institu

126 abase at the University Hospital Essen, Skin Cancer Center, Essen, Germany, was used to identify a co

127 titute-designated comprehensive and clinical cancer centers for oncology trials using advanced imagin

128 In order to meet that challenge, four cancer centers formed the Text Information Extraction Sy

129 Clinical advertisements by cancer centers frequently promote cancer therapy with em

130 ear HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were Washington

131 eated at The University of Texas MD Anderson Cancer Center from 1993 to 2007 and 4,590 patients from

132 l genetics service at a single tertiary care cancer center from 1998 through 2015.

133 isolated from patients at the M.D. Anderson Cancer Center from 2001 to 2010 and assessed their clini

134 t included bevacizumab at a comprehensive US cancer center from 2004 to 2007; date of last follow-up

135 ay inhibitor, vismodegib, at a comprehensive cancer center from 2009 through 2015.

136 ord review was conducted at a large tertiary cancer center from a prospectively maintained database f

137 HSCT at The University of Texas MD Anderson Cancer Center from January 1, 1997, to December 31, 2011

138 80 PET/CT scans performed at a comprehensive cancer center from January 2007 to January 2015 identifi

139 enting to an outpatient clinic at a tertiary cancer center from June 2006 to July 2009.

140 ucted at The University of Texas MD Anderson Cancer Center from May 10, 2011, to March 31, 2017, a to

141 ons of melphalan at Memorial Sloan Kettering Cancer Center from September 12, 2012, through April 15,

142 data were collected from 7 international eye cancer centers from January 1, 1980 through December 31,

143 ective multicenter study that involved 6 eye cancer centers from January 1, 1980, through December 31

144 of Health criteria, Memorial Sloan Kettering Cancer Center GIST nomogram, and American Joint Committe

145 thermore, high-volume centers and designated cancer centers had higher readmission rates.

146 ntimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primar

147 Although many cancer centers have adopted these tools as reflex LS scr

148 Few academic cancer centers have been QOPI participants.

149 These NCI-designated cancer centers have been shown to have better outcomes f

150 addition, high-volume centers and designated cancer centers have higher readmission rates, which may

151 udy at The University of Texas M.D. Anderson Cancer Center (Houston, Texas, 2000-2005), the authors d

152 CLC from The University of Texas MD Anderson Cancer Center (Houston, TX) and 293 cases from the Mayo

153 ystemic therapy were enrolled at MD Anderson Cancer Center (Houston, TX, USA) between Sept 15, 2014,

154 d control groups were treated at MD Anderson Cancer Center (Houston, TX, USA) from 1997 to 2015.

155 tients with high-risk CLL at the MD Anderson Cancer Center (Houston, TX, USA).

156 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

157 nting at The University of Texas MD Anderson Cancer Center (Houston, TX, USA).

158 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA).

159 nstitutions (University of Texas MD Anderson Cancer Center, Houston, and Siriraj Hospital, Mahidol Un

160 e feasibility trial performed at MD Anderson Cancer Center, Houston, Texas, included 12 patients with

161 urred at the University of Texas MD Anderson Cancer Center, Houston, TX, from 2002 to 2014.

162 o independent studies among 735 (MD Anderson Cancer Center, Houston, TX, USA) and 253 (Harvard Univer

163 We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and

164 en at a National Cancer Institute-designated cancer center (HR, 0.77; 95% CI, 0.62-0.97), and being s

165 e regions as the subset of 27 NCI-Designated Cancer Centers identified as National Comprehensive Canc

166 At a cancer center in Alberta, Canada, consecutive patients w

167 ncer with insomnia recruited from a tertiary cancer center in Calgary, Alberta, Canada, from Septembe

168 ented to the University of Texas MD Anderson Cancer Center in Houston during the period from January

169 at an outpatient supportive care center in a cancer center in Houston, Texas, including English-speak

170 al Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach c

171 North Shore Cancer Center, a community-based cancer center in northeastern Massachusetts.

172 ashington Cancer Consortium, a comprehensive cancer center in Seattle that serves the Pacific Northwe

173 European descent recruited from MD Anderson Cancer Center in the primary scan, and validated the top

174 at a federally funded tertiary care referral cancer center in Trujillo, Peru, from February 1 through

175 1, 1980, through December 31, 2015, at 6 eye cancer centers in 4 countries.

176 h 27 surgeons from 20 tertiary gynecological cancer centers in Australia, New Zealand, and Hong Kong

177 controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada

178 adenocarcinomas performed at two high-volume cancer centers in London between 2000 and 2010.

179 ospective cohort study including 14 regional cancer centers in Ontario, Canada.

180 melanomas in 134 patients treated in 9 skin cancer centers in Spain, France, Italy, and Austria.

181 rial was undertaken within eight gynecologic cancer centers in the Netherlands.

182 , and December 31, 2012, at 7 major academic cancer centers in the United States and Canada.

183 Patients from 5 liver cancer centers in the United States who had liver resect

184 2009 to 2013 at 4 academic tertiary referral cancer centers in the United States.

185 -institution academic national comprehensive cancer center included 527 consecutive patients with HER

186 al Cancer Institute-designated comprehensive cancer center included all patients undergoing curative-

187 The current state of palliative care in cancer centers is not known.

188 Many cancer centers lack a system of psychosocial care that i

189 m of Research Excellence and the Leon Berard Cancer Center, Lyon, France.

190 ted death, the experience of a comprehensive cancer center may be informative.

191 risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial.

192 encing on 29 TNBC cases from the MD Anderson Cancer Center (MDACC) selected because they had either p

193 recruited from the Memorial Sloan Kettering Cancer Center; Melanoma Unit of the Hospital Clinic, Uni

194 Tumor specimens were collected from Baptist Cancer Center (Memphis, Tennessee) over the course of 9

195 erson Lung Cancer Priority Fund, MD Anderson Cancer Center Moon Shot Initiative, and Cancer Center Su

196 of disease seen at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1992 and 2004, who ultimat

197 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA.

198 WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

199 WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

200 Patients were recruited from a tertiary cancer center (n=101) and three public hospitals treatin

201 MD Anderson Cancer Center, National Cancer Institute.

202 al Cancer Institute-designated Comprehensive Cancer Centers (NCI-CCCs), 50 randomly selected American

203 Cancer centers (NCI-CCs and CoC centers) were more likel

204 groups: National Cancer Institute-Designated Cancer Centers (NCI-CCs), Commission on Cancer (CoC) cen

205 validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, USA) from August, 2006, to

206 recruited from the Memorial Sloan-Kettering Cancer Center (New York, USA) were assessed.

207 performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were asses

208 all accuracy of the Memorial Sloan Kettering Cancer Center nomogram was higher in the ePLND+SNB than

209 ions of the updated Memorial Sloan Kettering Cancer Center nomogram.

210 implementation science program at the Butaro Cancer Center of Excellence in Rwanda are described as a

211 nsion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC

212 reatic adenocarcinoma from the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (Win

213 an HSCT from 1997 to 2011 at the MD Anderson Cancer Center of whom 602 (8%) developed a fracture.

214 RTICIPANTS Retrospective study at 2 academic cancer centers of 86 adult patients referred for clinica

215 er centers and a random sample of 71 non-NCI cancer centers of both executives and palliative care cl

216 Many cancer centers offer acupuncture services.

217 e cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

218 nts or relatives at Memorial Sloan Kettering Cancer Center or three related community hospice program

219 d at National Cancer Institute Comprehensive Cancer Centers or Veterans' Affairs institutions (all ca

220 Eye Cancer Center, Beth Israel Comprehensive Cancer Center, or The New York Eye and Ear Infirmary bet

221 al adenocarcinoma were recruited at a single cancer center over a 2-year period.

222 were those who practiced at a comprehensive cancer center (P = 0.06) and attended tumor board meetin

223 Cancer center patients had a significantly higher Charls

224 Cancer center patients had a significantly higher in-hos

225 Cancer center patients had a significantly longer hospit

226 r center (8.6% [95% CI, 8.1%-9.2%] among NCI cancer center patients vs 6.0% [95% CI, 5.9%-6.1%] among

227 Of the 557 patients, 135 were cancer center patients.

228 ts vs 6.0% [95% CI, 5.9%-6.1%] among non-NCI cancer center patients; odds ratio [OR], 1.13 [95% CI, 1

229 Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC; www.helmholtz-pccc.de) hosted the "

230 Cancer centers performed better on 3 of 4 process measur

231 Accredited cancer centers performed better on most process and pati

232 A total of 102 cancer centers placed 409 unique clinical advertisements

233 ior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group, to receive the combinati

234 006, 98 patients at Memorial Sloan-Kettering Cancer Center received induction therapy with four cycle

235 Cancer center recognition, offered as accreditation by t

236 ing high-dose ara-C (HiDAC) at M.D. Anderson Cancer Center refractory to 1 cycle of induction were co

237 f oncologists affiliated with NCI-Designated Cancer Centers relative to oncologists excluded from the

238 Most cancer centers reported a palliative care program, altho

239 ion in institutional practice manifest among cancer centers reveals a lack of consensus about optimal

240 hools of public health, medical schools, and cancer centers, revised competencies and training progra

241 Memorial Sloan Kettering Cancer Center risk category was favorable in 26% of pati

242 n was stratified by Memorial Sloan Kettering Cancer Center risk group and papillary histology.

243 cation factors were Memorial Sloan Kettering Cancer Center risk group and the number of previous trea

244 Geriatricians at Memorial Sloan Kettering Cancer Center risk-stratify surgical patients with solid

245 databases at three institutions: MD Anderson Cancer Center, Smilow Cancer Hospital at Yale, and The J

246 ) was analyzed, independent of HV esophageal cancer center status and patient and disease-specific co

247 rson Cancer Center Moon Shot Initiative, and Cancer Center Support (Core), National Cancer Institute,

248 utes of Health and National Cancer Institute Cancer Center Support Grant P30 CA008748.

249 Treatment of Cancer, NIH through MD Anderson Cancer Center Support Grant, and the MD Anderson MDS & A

250 ichard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.

251 ion for Health Research and Development, NCI Cancer Center Support, NCI Clinical and Translational Sc

252 l Cancer Care biobanking protocol at Moffitt Cancer Center (Tampa, FL, USA) between Jan 1, 2006, and

253 an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advance

254 In a tertiary cancer center, the 12-LN threshold was not relevant and

255 the NCCN, a consortium of multidisciplinary cancer centers, the use of BCS and mastectomy with recon

256 Results In regions containing NCI-Designated Cancer Centers, there were 13.7 oncologists per 100,000

257 f oncologists associated with NCI-Designated Cancer Centers; this relationship held when considering

258 nt one approach we took at Vanderbilt-Ingram Cancer Center to address these challenges.

259 likely than patients treated at the tertiary cancer center to be in the high-symptom group (odds rati

260 une 2000 to March 2010 at the M. D. Anderson Cancer Center to develop and test genomic predictors for

261 more likely than those treated at a tertiary cancer center to experience substantial symptoms during

262 ished nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients wi

263 ced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 common symptoms via tablet co

264 fertility program was established at a large cancer center to support clinicians in discussing treatm

265 administered in community-based and academic cancer centers to 287 women 40 years or older with stage

266 e need for specialized designation of rectal cancer centers to support ongoing regionalization of car

267 e need for specialized designation of rectal cancer centers to support ongoing regionalization of car

268 y of California, San Francisco Comprehensive Cancer Center Tobacco Program.

269 study at the University of Texas MD Anderson Cancer Center, TX, USA.

270 riation in chemotherapy and radiation use by cancer center type, geographical location, and hospital

271 ceived frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leu

272 of a prospective clinical trial at the Skin Cancer Center, University Hospital Essen.

273 al Cancer Institute-designated comprehensive cancer center varied considerably in how they planned to

274 ow using Ohio State University Comprehensive Cancer Center version 3.0 arrays in 187 younger (<60 yea

275 he disease-specific survival adjusted by eye cancer center was better in patients who had received ri

276 y collected data at Memorial-Sloan Kettering Cancer Center was conducted.

277 elective operations (n = 503) at a tertiary cancer center was conducted.

278 tudy conducted in three French comprehensive cancer centers was to evaluate the therapeutic impact on

279 udy from The University of Texas MD Anderson Cancer Center, we assessed the associations of 19,830 co

280 At Memorial Sloan Kettering Cancer Center, we have focused our energies on imaging s

281 th CNS inflammatory diseases at the National Cancer Center were analysed using cell-based assays for

282 2014 at The University of Texas MD Anderson Cancer Center were identified and immunophenotypically c

283 a 5-year period at Memorial Sloan-Kettering Cancer Center were identified from an electronic medical

284 breast cancer at the Lombardi Comprehensive Cancer Center were included in this study.

285 b at The Ohio State University Comprehensive Cancer Center were included.

286 ber 2009 and October 2014 at the MD Anderson Cancer Center were included.

287 ans from 2002 to 2013 at the Peter MacCallum Cancer Center were retrospectively analyzed, and a syste

288 atients from 2000 to 2010 at the MD Anderson Cancer Center were used to develop the clinical predicti

289 a (DLBCL) diagnosed from 2000-2010 at 7 NCCN cancer centers were assessed for their prognostic signif

290 Program directors at all NCI and NCCN cancer centers were invited to participate in the study.

291 Seven eye cancer centers were involved in the study.

292 al Cancer Institute-designated comprehensive cancer centers were randomly sampled and surveyed to eva

293 National Cancer Institute cancer centers were significantly more likely to have a

294 node-negative breast cancer patients at our cancer center who had undergone surgery as their first t

295 other concurrent patients at the MD Anderson Cancer Center who were eligible for this trial but decli

296 Patients at a tertiary cancer center with chronic pain or dysfunction attribute

297 rt study, genomic DNA of women from 12 major cancer centers with a first diagnosis of invasive breast

298 enitourinary, or breast cancer at a tertiary cancer center, with access to a home computer and prior

299 single National Cancer Institute-designated cancer center within a quaternary academic medical cente

300 National Cancer Institute (NCI) -designated cancer centers within federal exchange networks.